ArticleThe Journal of experimental medicine2021
Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 53 citations in OpenAlex.
- Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity.bioRxiv : the preprint server for biology · 2026Article
- Tick-borne viruses: discovery, clinical aspects, influencing factors and control.Nature reviews. Microbiology · 2026Review
- Article
- Underrecognized Tick-Borne Encephalitis in Serbia: Evidence from Patients with Suspected West Nile Virus Neuroinvasive Disease.Pathogens (Basel, Switzerland) · 2026Article
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026Article
- Tick-Borne Co-Infection in Lyme Disease: Clinical Impact, Diagnostic Challenges, and Therapeutic Perspectives.Microorganisms · 2026Review
- Tick-Borne Encephalitis in the 21Le infezioni in medicina · 2026Review
- Nanobody conjugated with dendrimer nanoparticles effectively neutralizes tick-borne encephalitis virus.Scientific reports · 2025Article
- Sex-dependent impairment of antibody responses to tick-borne encephalitis virus vaccination and infection in obese mice.The Journal of general virology · 2025Article
- Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain.mSphere · 2025Article
- The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.NPJ vaccines · 2025Article
- Enhanced RNAi does not provide efficient innate antiviral immunity in mice.Nucleic acids research · 2025Article
- Mature dengue virus particles inactivated by a non-ionic detergent retain quaternary neutralizing epitopes and induce potent neutralizing antibodies.Frontiers in immunology · 2025Article
- Methods for Evaluation of Antivirals and Neutralizing Antibodies Against Tick-Borne Encephalitis Virus.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The structure of inactivated mature tick-borne encephalitis virus at 3.0 Å resolution.Emerging microbes & infections · 2024Article
- Structural diversity of tick-borne encephalitis virus particles in the inactivated vaccine based on strain Sofjin.Emerging microbes & infections · 2024Article
- Poor virus-specific T-cell responses early after tick-borne encephalitis virus infection correlate with disease severity.Emerging microbes & infections · 2024Article
- Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in ∼10% of patients.The Journal of experimental medicine · 2024Article
- Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins.NPJ vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 4 countries.
Funding
Abstract
Tick-borne encephalitis virus (TBEV) is an emerging human pathogen that causes potentially fatal disease with no specific treatment. Mouse monoclonal antibodies are protective against TBEV, but little is known about the human antibody response to infection. Here, we report on the human neutralizing antibody response to TBEV in a cohort of infected and vaccinated individuals. Expanded clones of memory B cells expressed closely related anti-envelope domain III (EDIII) antibodies in both groups of volunteers. However, the most potent neutralizing antibodies, with IC50s below 1 ng/ml, were found only in individuals who recovered from natural infection. These antibodies also neutralized other tick-borne flaviviruses, including Langat, louping ill, Omsk hemorrhagic fever, Kyasanur forest disease, and Powassan viruses. Structural analysis revealed a conserved epitope near the lateral ridge of EDIII adjoining the EDI-EDIII hinge region. Prophylactic or early therapeutic antibody administration was effective at low doses in mice that were lethally infected with TBEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.